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Stem Cell Grafts Deliver Enzyme Replacement
to Affect CNS Disease in Sanfilippo B Mice
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Brooklyn, NY 11215, USASanfilippo syndrome type B (mucopolysaccharidosis type IIIB
[MPS IIIB]) is a lysosomal storage disorder primarily affecting
the brain that is caused by a deficiency in the enzyme a-N-ace-
tylglucosaminidase (NAGLU), leading to intralysosomal accu-
mulation of heparan sulfate. There are currently no treatments
for this disorder. Here we report that, ex vivo, lentiviral correc-
tion of Naglu/ neural stem cells derived from Naglu/ mice
(iNSCs) corrected their lysosomal pathology and allowed them
to secrete a functional NAGLU enzyme that could be taken up
by deficient cells. Following long-term transplantation of these
corrected iNSCs into Naglu/ mice, we detected NAGLU ac-
tivity in the majority of engrafted animals. Successfully
transplanted Naglu/ mice showed a significant decrease in
storage material, a reduction in astrocyte activation, and
complete prevention of microglial activation within the area
of engrafted cells and neighboring regions, with beneficial
effects extending partway along the rostrocaudal axis of the
brain. Our results demonstrate long-term engraftment of
iNSCs in the brain that are capable of cross-correcting pathol-
ogy in Naglu/ mice. Our findings suggest that genetically
engineered iNSCs could potentially be used to deliver enzymes
and treat MPS IIIB.Received 24 April 2018; accepted 7 June 2018;
https://doi.org/10.1016/j.omtm.2018.06.005.
3These authors contributed equally to this work.
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Mucopolysaccharidosis type IIIB (MPS IIIB), an inherited lysosomal
disorder, is a sub-type of MPS III caused by deficiency of a-N-acetyl-
glucosaminidase (EC 3.2.1.50 [NAGLU]), a lysosomal acid hydrolase
that normally degrades heparan sulfate.1 Heparan sulfate proteogly-
cans bind many ligands, modulate numerous cellular activities, and
aid in tissue architecture and physiology.2 Accumulation of heparan
sulfate is associated with neurological dysfunction in MPS III,
although the mechanism by which this may occur is not precisely
known.
Children with MPS IIIB have severe neurological and behavioral def-
icits, generally leading to death in the first 20–30 years of life.1 There is
currently no effective treatment for MPS IIIB, and the clinical man-
agement of the disease is mainly symptomatic or palliative.3 So far,
research has focused on enzyme replacement therapy (ERT), geneMolecular Therapy: Methods & Clini
This is an open access article under ttherapy, hematopoietic stem cell transplantation, and substrate
reduction to treat MPS IIIB, but these approaches have not been as
successful as for other MPS diseases with less CNS involvement,
largely because they have not been effectively targeted to the brain.
For example, systemic ERT has been successful in treating some types
of MPS with extensive somatic involvement (MPS I,4 II,5 IVA,6
and VI7), but this approach is not feasible for MPS IIIB because of
the inability of the NAGLU enzyme to cross the blood-brain barrier
and alleviate the neurological deficits associated with MPS IIIB.
Nonetheless, this problem could potentially be solved if the missing
enzyme could be delivered to the brain via the cerebrospinal fluid
(CSF), although life-long repeated administration would still be
required.8
Gene therapy is an attractive tool for the treatment of monogenic dis-
orders like MPS IIIB.9–11 By delivering AAV9 vectors encoding
NAGLU to the CSF of MPS IIIB mice, it was shown that the pattern
of gene expression in the brain can be restored to that of healthy an-
imals, giving rise to normal enzymatic activity. This results in the
normalization of GAGs and Lamp 1 staining, a surrogate marker
for lysosomal physiology, and resolution of the neuroimmune
response together with the reversal of behavioral deficits and an
extended lifespan.10 Nevertheless, the promise of such gene therapy
approaches has yet to be fulfilled clinically, and neural stem cells
(NSCs) provide an alternative means to deliver enzymes to the brain.
Hematopoietic stem cell transplantation is currently available as a
life-saving treatment for MPS I patients with CNS involvement but
has not been effective for MPS IIIA,12 presumably because of the
low levels of either grafted cells or enzymes that reach the brain.13
One possible solution would be direct implantation of NSCs intocal Development Vol. 10 September 2018 ª 2018 The Authors. 113
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Characterization of Induced Pluripotent
Stem Cells and Neural Stem Cells
(A–C) Naglu/ iPSCs growing on feeder mouse embry-
onic fibroblasts (MEFs). (A) Phase contrast image, alkaline
phosphatase staining, and Oct-4 (red) staining merged
with nuclear staining (DAPI, blue). Scale bars, 200 mm
(phase contrast) and 400 mm (alkaline phosphatase and
Oct4). (B) Real-time qPCR probing Nestin gene expres-
sion after differentiation of iPSCs to neural stem cells
(iNSCs; n = 5, p = 0.0005). Mean with SD. (C) Immuno-
staining of iNSCs with Nestin (red). Scale bar, 500 mm.
(D–F) iNSCs were further differentiated into different cell
types characterized by antibodies against Map2 and
Tuj-1 (neuron markers) (D), GFAP (astrocyte marker)
(scale bar represents 500 mm) (E), and Olig1 (oligoden-
drocyte marker) (scale bars represent 100 mm) (F). Nu-
clear staining with DAPI (blue) was overlaid in (C)–(F).
Post-acquisition processing included adjustment of
brightness and contrast in (C)–(F) using Adobe Photoshop
CS6 to reduce over-exposure. ***p < 0.001.
Molecular Therapy: Methods & Clinical Developmentthe brain to provide a relatively long-term supply of secreted enzymes
to the CNS.14 Such NSCs can engraft and reduce lysosomal storage in
MPS VII mice15,16 and other lysosomal storage disorders.17 Most
studies have used NSC lines isolated from various sources, but
another possibility is the development of induced pluripotent stem
cells (iPSCs) to generate NSCs. The benefit of this approach is that
gene-corrected NSCs could be developed from patient-derived iPSCs,
providing a more optimal graft for transplantation by avoiding the
issue of immune rejection.
Here we reprogrammed Naglu/ mouse embryonic fibroblasts
(MEFs) into iPSCs and corrected them ex vivo using a lentiviral vector
to drive human NAGLU overexpression. We showed that corrected
NSCs derived from these iPSCs expressed and secreted functional
NAGLU in vitro and corrected their lysosomal defects. Upon intra-
cranial transplantation of these corrected NSCs into Naglu/ mice
from birth, NAGLU activity was partially restored. Engrafted cells114 Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018produced a marked reduction in lysosomal pa-
thology and astrocytosis and reduced micro-
glial activation to normal levels. These data
also provide a promising proof of principle
for this approach and pave the way to perform-
ing similar approaches to treat MPS IIIB
patients with their own derived and corrected
iPSCs.
RESULTS
Characterization of iPSCs and NSC
Derivation and Differentiation
Naglu/ MEFs were reprogrammed to iPSCs
using lentiviral transduction of OCT4, KLF4,
SOX2, and c-MYC.18 Morphology, alkaline
phosphatase staining, and immunofluores-cence for Oct4 were used to confirm their pluripotency (Figure 1A).
iPSC clones were differentiated to NSCs (iNSCs) as described previ-
ously,19 and Nestin (an NSCmarker) was expressed at the mRNA and
protein levels (Figures 1B and 1C). The iNSCs were further differen-
tiated into neurons, astrocytes, and oligodendrocytes to show their
neural and glial lineage potential (Figures 1D–1F). These differenti-
ated cells showed an appropriate cell type-specific morphology and
stained positively for the phenotypic markers Tuj1 and Map2, glial
fibrillary acidic protein (GFAP), and Olig1, respectively. These results
demonstrate thatNaglu/MEFs can not only be successfully reprog-
rammed to iPSCs but were also capable of differentiating into neurons
and glia of the appropriate lineage.
NAGLU Gene Therapy and Subsequent Biochemical
Characterization
To correct the MPS IIIB-associated genetic defects, we overexpressed
full-length human NAGLU cDNA in Naglu/ iNSCs using lentiviral
Figure 2. NAGLU Gene Therapy and Subsequent Biochemical Characterization
(A) FACS analysis of Naglu/ iNSCs (white) transduced with NAGLU-GFP (black). (B and C) Quantifying secreted (C) and intracellular (B) NAGLU enzyme activity in iNSCs
overexpressing NAGLU (N-iNSCs). Student’s t test, p < 0.0001 and p = 0.0047, respectively. (D) Cellular uptake and inhibition assay on iNSCs (Naglu/) treated with
supernatant collected from N-iNSCs in the presence or absence of 5 mM mannose-6-phosphate (M6P). n = 4, one-way ANOVA, p < 0.0001. (B–D) Mean with SD.
Intracellular NAGLU activity is presented as units per milligram of protein, whereas the secreted NAGLU activity is presented as units per milliliter expressed as mean ± SD,
where a unit is defined as the release of 1 nmol of 4-MU per hour at 37C. **p < 0.01, ****p < 0.0001.
www.moleculartherapy.orgtransduction. The viral construct also carried a GFP reporter, and,
following transduction, the cells were sorted using fluorescence-acti-
vated cell sorting (FACS) to ensure pure, unsilenced expression of
NAGLU (Figure 2A). We refer to corrected cells as N-iNSCs.
N-iNSCs had intracellular NAGLU activity 4-fold greater than the
wild-type (WT) and secreted NAGLU at a level 14-fold greater
than the WT (Figures 2B and 2C).
Previous attempts to produce recombinant NAGLUhave resulted in a
poorly phosphorylated enzyme that demonstrates little to no intracel-
lular uptake.20–22 To determine whether the NAGLU secreted from
our N-iNSCs was able to enter Naglu/ cells in a mannose-6-phos-
phate (M6P)-dependent manner, we performed cellular uptake assays
with an excess amount of M6P to inhibit NAGLU uptake via M6P re-
ceptors (M6PRs). We harvested supernatant from N-iNSCs and
applied it to Naglu/ iNSCs in the presence or absence of 5 mM
M6P. After 4 hr of treatment, NAGLU activity reached a mean of
6.5% ± 1.15% of WT levels. Intracellular uptake was completely in-
hibited in the presence of 5 mMM6P (Figure 2D). These data provide
evidence that N-iNSCs secreted an appropriately phosphorylated
NAGLU that is capable of cross-correctingNaglu/ cells via M6PRs.
A hallmark of MPS IIIB disease in patients and also in Naglu/mice
is enlarged lysosomes. To quantify the effect of NAGLU secreted from
N-iNSCs on lysosomal size, we used LysoTracker, a fluorescent acid-
otropic probe for labeling and tracking acidic organelles in live cells.23
We measured the frequency and mean intensity of the signal in Lyso-
Tracker-positive cells using FACS.24 We speculated that Naglu/
mouse-derived iNSCs would have larger lysosomes compared with
WT NSCs and that, upon treatment with NAGLU-containing super-
natant, the size of their lysosomes would return to WT level. How-
ever, we did not detect significant differences in the frequency ofMolecular TheNaglu/ iNSCs with a high LysoTracker signal compared with
WT NSCs or any changes in their mean LysoTracker signal intensity
(Figures S1A and S1B). Because autophagy is upregulated in NSCs to
fulfil their high energy demand,25 and because this process requires
membrane fusion to lysosomes,26 an altered LysoTracker signal
would be more readily detected in differentiated NSCs, and this might
reveal differences between iNSCs of different genotypes. Therefore,
we differentiated NSCs into neuronal and glial lineages (NSC
Nestin) and measured their LysoTracker signal. When the iNCSs
were differentiated, the frequency of cells with a higher LysoTracker
signal was greater in Naglu/ cells compared with WT cells. Upon
treatment with conditioned medium from our lentivirally corrected
N-iNSC cells, Naglu/ cells showed a 63% decrease in the frequency
of cells with a high LysoTracker signal and a 10-fold decreased mean
LysoTracker signal intensity (Figures S1C and S1D).
NSCs Engraftment
We next grafted N-iNSCs into newborn Naglu/mice to assess their
distribution and the subsequent effect of secreted NAGLU on disease-
associated neuropathology in vivo. We independently used two
different routes to deliver N-iNSCs; they were either injected bilater-
ally into the lateral ventricles (intracerebroventricular [ICV]) or the
striatum (intraparenchymal; PAR in Figure 3A). Two months after
transplantation, we examined the forebrain for evidence of N-iNSC
engraftment. The left hemisphere was fixed and cut into 40-mm cor-
onal sections for GFP immunohistochemistry (Figure 3B). The right
hemisphere was used for evaluation of GFP expression using flow cy-
tometry analysis (FACS) and NAGLU enzyme activity for both ICV
and intraparenchymal injections (Figures 3C and 3D).
GFP-positive cells were detected in five of six ICV-grafted animals, as
measured by FACS (Figure 3C). 1%–5% of residual enzyme activity israpy: Methods & Clinical Development Vol. 10 September 2018 115
Figure 3. NAGLU Corrected N-iNSC Grafting after 2
Months
(A) Annotated image of the parameters for intra-
cerebroventricular (ICV, green) and intraparenchymal (PAR,
blue) injections. X indicates represented injection sites. (B)
Immunohistological staining of 40-mm representative sec-
tions forGFP, shown in lowmagnification, following ICV and
intraparenchymal transplantion of N-iNSCs at birth (cells
have a GFP reporter) in Naglu/ mice 2 months after
transplantation. Post-acquisition processing included ad-
justments to brightness and contrast and red green blue
(RGB) curves using Adobe Photoshop CS6 to improve vis-
ibility and consistency in color tone. Scale bar, 1 mm. Ros-
trocaudal distribution of N-iNSCs relative to the level of
greatest engraftment is shown in millimeters (bottom left
corner). FACS analysis showing percentage engraftment
(C and D, top) and NAGLU enzyme activity assays are
shown in units per milligram of protein (C and D, bottom),
performed on brain lysates following ICV and intra-
parenchymal injection (n = 6 in each treatment).
Molecular Therapy: Methods & Clinical Developmenttypically considered sufficient to correct storage accumulation in lyso-
somal storage disorders (LSDs).27,28 NAGLU activity levels in two of
six animals were greater than 5% of the level present in unaffected
controls (Figure 3D). Similarly, FACS analysis showed that five of
six intraparenchymally grafted animals possessed GFP-positive cells,116 Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018but four of six transplanted animals had NAGLU
activity greater than 5% of unaffected animals.
When injected via ICV, NSCs need to cross the
ependyma to spread into the parenchyma, posing
a challenge for the cells to efficiently graft, result-
ing in a lower number of grafted animals using
this route.
To determine where the cells had engrafted, we
immunostained the brain sections to identify
GFP-positive cells. Figure 3B shows the relative
amount and distribution of N-iNSC engraftment
in ICV and intraparenchymally grafted brains.
Relatively few cells were detected in the paren-
chyma of ICV grafted brains, with a limited ros-
trocaudal spread of no more than 0.5 mm in
either direction from the injection site. The ma-
jority of GFP-positive cells in these ICV-grafted
brains were located within the lateral septum
and the dorsal border of the lateral ventricle,
with fewer cells within and above the corpus
callosum in the motor cortex (Figure 3B).
In contrast, N-iNSC engraftment was markedly
greater in the brains of intraparenchymally
grafted animals, with GFP-positive cells present
over a greater rostrocaudal distance of at least
1.5 mm away from the site of injection. The ma-jority of these GFP-positive cells were within the ventral and ventro-
lateral forebrain, within the globus pallidus, ventral pallidum, and
piriform cortex, extending caudally into nuclei of the amygdala, as
well as the ventral and lateral striatum itself (Figure 3B). Fewer
GFP-positive cells could also be detected along the fiber tracts of
(legend on next page)
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Molecular Therapy: Methods & Clinical Developmentthe corpus callosum separating the striatum from the cerebral cortex
(Figure 3B). In addition, a small number of cells was detected in and
around the hippocampal formation (Figure 3B), with no preference
for any particular subfield.
Effect of N-iNSCs upon Microglial Activation
A neuroimmune response is a common feature of MPS IIIB,29–31 and
Naglu/ mice show pronounced microglial activation.11,30,31 To
assess whether N-iNSCs had any effect upon microglial activation,
we stained sections of unaffected control (Naglu+/), vehicle-injected
Naglu/ (/ vehicle), and iNSC-grafted Naglu/ (/ treated)
brains for the microglial marker CD68. Thresholding image analysis
was then used to quantify the effect ofN-iNSCs upon CD68 immuno-
staining both close to the site of maximum engraftment (local effects
of grafts, within the motor cortex and dorsal striatum in ICV mice,
and within the ventral forebrain in intraparenchymally grafted
mice) and further away (within the ventral striatum) in ICV-grafted
mice and in the motor cortex in intraparenchymally grafted mice to
assess the potential effect of secreted enzyme to cross-correct pathol-
ogy (Figure 4A).
As expected, there was significantly more CD68 immunoreactivity in
vehicle-injected Naglu/ mice compared with unaffected control
mice, and this could be seen in widespread brain regions (Figures
4B and 4C). At high magnification, these microglia were darkly
stained and rounded in shape, typical of activated microglia (Fig-
ure 4C, 1–3).
For both ICV and intraparenchymally grafted brains, graded effects
on the distribution of CD68 immunoreactivity were observed (Fig-
ure 4B), with much less staining for this marker and more pro-
nounced effects on microglial morphology closer to the sites of
engraftment. In the ICV-grafted brains, where most of the N-iNSC
cells were found in the septum, CD68 staining was markedly reduced
in the surrounding regions (Figure 4B) but remained more intense
farther away from these sites, revealing what appeared to be a bound-
ary beyond which grafts did not influence microglial activation to the
same extent. Indeed, these effects were evident both dorsally in the
motor cortex and in the striatum, suggesting a therapeutic effect ex-
tending in both directions from the site of engraftment. Close to
the ventricles, where the greatest number of cells engrafted in ICV
mice, the level of CD68 staining resembled that of the unaffectedFigure 4. Reduction of Microglial Activation in Naglu–/– Mice Treated with Neu
(A) Schematic illustration of ICV injection (green) at the bregma (1.54mm) and PAR inject
relative to the site of engraftment (ICV and PAR), including themotor cortex, striatum, and
of half-brain coronal sections of immunohistochemical staining of CD68 in amouse inject
and vehicle-injectedNaglu/mice (/ vehicle). Scale bar, 1mm. The locations of ICV a
outline regions where CD68 staining is less pronounced, indicating a reduction of microg
(2), and ventral forebrain (3) of immunohistological staining for CD68 in/ vehicle comp
injection. Scale bars, 100 mm. The blue dotted lines highlight the difference in CD68 imm
(dark blue box) in ICV-injected brains. Inset images were taken at higher magnification
20 mm. Post-acquisition processing was applied to all images and included adjustments
visibility and consistency in color tone. The histograms on the right show the area of CD
two-tailed, unpaired parametric t test. Values are shown as mean ± SEM (n = 3 mice p
118 Molecular Therapy: Methods & Clinical Development Vol. 10 Septebrains (Figure 4C, 1), and thresholding image analysis showed this
effect of ICV grafts to be significant, whereas, farther away from the
ventricle, CD68 immunoreactivity remained quantitatively at a level
similar to vehicle-injected Naglu/ mice, albeit appearing morpho-
logically less activated (Figure 4C, 1). Farther away in the striatum of
ICV-grafted mice, the level of CD68 immunostaining was partly
reduced compared with untreated Naglu/mice by approximately
half, but this was not significant statistically (p = 0.0808; Figure 4C, 2).
When CD68 immunoreactivity was analyzed within the ventral fore-
brain of ICV-grafted animals (at the greatest distance from where
the engrafted cells were detected), we saw an even smaller reduction
in CD68 immunoreactivity compared with the striatum and motor
cortex (Figure 4C, 3).
A similar overall reduction in microglial activation was observed in
intraparenchymally grafted animals compared with vehicle-injected
Naglu/ mice (Figure 4B). Within the motor cortex of the intrapar-
enchymally grafted animals (at the greatest distance from where most
of the N-iNSC cells had engrafted), we observed a 1.3-fold reduction
in CD68 immunoreactivity and fewer large intensely stained ameba-
shaped microglia compared with vehicle-injected Naglu/ mice
(Figure 4C, 1). In contrast, when we analyzed the striatum and the
ventral forebrain of intraparenchymally grafted animals versus
vehicle-injected controls, we observed highly significant 7-fold
(p = 0.0004) and 35-fold (p = 0.0001) reductions in CD68 immuno-
reactivity, respectively. In these regions, CD68 staining was no
different than the unaffected mice, and these CD68-positive microglia
had a highly ramified morphology and small cell body typical of
resting or less activated microglia (Figure 4C, 2 and 3).
Effect of N-iNSC on Astrocytosis
Another common feature of the innate immune response in MPS
IIIB is astrocytosis,31 which can be revealed by GFAP immunostain-
ing. The level of GFAP immunostaining in vehicle-treated Naglu/
mice ranged between regions from 1.5- to 4-fold higher than unaf-
fected mice among the motor cortex, striatum, and ventral forebrain
(Figures S2A and S2B) and was highly significant regardless of iNSC
delivery route (Figures S2B and S2C, 1–3). A readily discernable
zone of reduced GFAP immunostaining was evident in the region
of grafted cells in intraparenchymally but not ICV-grafted brains
(Figure S2B). In these ICV-grafted animals, no difference in
GFAP immunoreactivity was apparent in N-iNSC-treated animalsral Stem Cells Overexpressing NAGLU
ion (blue) at the bregma (0.58mm), demonstrating regions of analysis (red squares)
ventral forebrain. (B) Representative bright-field images taken at a lowmagnification
edwithN-iNSCs (/ treated) comparedwith unaffected heterozygous (unaffected)
nd intraparenchymal injections are outlined by red dotted lines. The blue dotted lines
lial activation. (C) Representative bright-field images of the motor cortex (1), striatum
ared with unaffected mice and in/ treated mice upon ICV and intraparenchymal
unoreactivity close to the ventricle (yellow box) versus farther away from the ventricle
to highlight the differences in morphology of CD68-stained microglia. Scale bars,
to brightness and contrast and RGB curves using Adobe Photoshop CS6 to improve
68 immunoreactivity for each group, measured. *p < 0.05, **p < 0.01, ***p < 0.001;
er group). Mean with SEM. For p values, see Tables 1 and 2.
mber 2018
Table 1. p Values for the Quantitative Analysis of Mice that Received
Postnatal ICV Injections of N-iNSCs and Controls
Area Comparison p Value
Figure 4
motor cortex
/ vehicle versus unaffected 0.0040
/ treated (ICV) versus unaffected 0.0026
/ treated (ICV) versus / vehicle 0.3121
striatum
/ vehicle versus unaffected 0.0002
/ treated (ICV) versus unaffected 0.0010
/ treated (ICV) versus / vehicle 0.0004
ventral forebrain
/ vehicle versus unaffected 0.0001
/ treated (ICV) versus unaffected 0.3397
/ treated (ICV) versus / vehicle 0.0001
Figure S2
motor cortex
/ vehicle versus unaffected 0.0020
/ treated (ICV) versus unaffected 0.0217
/ treated (ICV) versus / vehicle 0.8758
striatum
/ vehicle versus unaffected 0.0009
/ treated (ICV) versus unaffected 0.0674
/ treated (ICV) versus / vehicle 0.4920
ventral forebrain
/ vehicle versus unaffected 0.0073
/ treated (ICV) versus unaffected 0.0209
/ treated (ICV) versus / vehicle 0.5806
Figure S3
motor cortex
/ vehicle versus unaffected 0.2262
/ treated (ICV) versus unaffected 0.1822
/ treated (ICV) versus / vehicle 0.5669
striatum
/ vehicle versus unaffected 0.0836
/ treated (ICV) versus unaffected 0.0591
/ treated (ICV) versus / vehicle 0.5910
ventral forebrain
/ vehicle versus unaffected 0.4431
/ treated (ICV) versus unaffected 0.3597
/ treated (ICV) versus / vehicle 0.8442
Definition of statistical significance: p < 0.05.
www.moleculartherapy.orgcompared with the vehicle-injected Naglu/ mice regardless of the
region analyzed, and thresholding image analysis confirmed this
(Figure S2C, 1–3). These findings indicate that the N-iNSC cells
had no effect on astrocyte activation in any brain region when in-
jected via the ICV route, even in areas close to where the cells en-
grafted. In intraparenchymally grafted mice, there was no effect of
the N-iNSC grafts on the level of GFAP immunoreactivity in the
motor cortex, but, closer to the sites of engraftment, there was a
significant decrease in GFAP staining in the striatum (1.7-fold
reduction, p = 0.0155) and ventral forebrain (1.5-fold reduction,
p = 0.0095) (Figure S2C, 1–3). Furthermore, the morphology of
GFAP-positive astrocytes, having thinner, more palely stained pro-
cesses and a smaller cell soma in intraparenchymally grafted
Naglu/ mice, resembled less activated astrocytes compared with
the intensely stained GFAP-positive astrocytes with thickened pro-
cesses and a hypertrophied cell body seen in other brain regions of
these mice and in vehicle-injected Naglu/ mice (Figure S2C).Molecular TheCorrection of Lysosomal Dysfunction and Storage Material
To evaluate the direct effect of the engrafted N-iNSCs on their lyso-
somal disease, we immunostained sections through the motor cortex,
striatum, and ventral forebrain for the lysosomal membrane protein
Lamp 1, which serves as a surrogate marker for lysosomal storage
accumulation (Figures S3A and S3B).32 As expected, Lamp 1 immu-
noreactivity was greater in vehicle-injected Naglu/ mutant mice
compared with unaffected heterozygous controls across all three areas
assessed, but this did not reach significance because of the high vari-
ation within the vehicle-injected controls, with the exception of the
striatum in the intraparenchymally grafted group (p = 0.0167, Figures
S3B and S3C). In the ICV-grafted brains, there was no decrease in
Lamp 1 immunoreactivity compared with vehicle-injected Naglu/
mice in any of the brain regions assessed (Figure S3C, 1–3). In the in-
traparenchymally grafted brains, Lamp 1 staining was markedly
decreased in the striatum and ventral forebrain and was not signifi-
cantly different from unaffected animals (Figure S3C).
Taken together, our results suggest that intraparenchymal delivery of
N-iNSCs results in a greater level of engraftment than the ICV route.
These engrafted N-iNSCs are capable of secreting sufficient enzymes
to correct disease-associated pathology, but this is limited to the area
where they reside and has a greater effect on microglial activation
than astrocytosis.
Long-Term Engraftment and Effect of N-iNSC on
Neuropathology and Lysosomal Dysfunction
Based on our data from a 2-month survival time, a second cohort of
mice was injected bilaterally into the parenchyma of the striatum at
birth and sacrificed 9 months after transplantation to qualitatively
assess the level and effects of longer-term engraftment. Ten mice
per group were included in this analysis, and GFP-positive cells
were detected in all but one animal. In the majority of the mice (seven
of ten), GFP-positive cells could be detected partway along the rostro-
caudal axis, with cells detected in the ventral and/or ventrolateral
forebrain, along the fiber tracts of the corpus callosum, and the sub-
stantia nigra, as shown in Figure 5A, which shows a mouse with a
high level of engraftment. In some brains, cells were also concentrated
in other regions. In one animal, for example, a striking number of
GFP-positive cells could be detected in the olfactory bulb and
throughout the dorsorostral striatum, directly beneath the anterior
forceps of the corpus callosum (data not shown).
Enzyme activity for the corresponding right hemisphere was evalu-
ated for the six rostrocaudal 2-mm slices, as shown in Figure 5B. In
our enzymatic assay, we combined sections 1 and 2 and sections
5 and 6. As expected, no NAGLU activity was detected in vehicle-in-
jected Naglu/mice (Figure 5C). In the pool of sections 1 and 2, the
averaged NAGLU activity in engrafted Naglu/mice reached a level
almost 5-fold above the level of unaffected mice (Figure 5C). In sec-
tions 3 and 4 and the pool of 5 and 6, NAGLU activity in engrafted
Naglu/ mice was significantly greater than in vehicle-injected
Naglu/ mice (p < 0.0001 for sections 3, p < 0.0001 for section 4,
and p = 0.0017 for sections 5 and 6) and reached approximatelyrapy: Methods & Clinical Development Vol. 10 September 2018 119
Table 2. p Values for the Quantitative Analysis of Mice that Received
Postnatal PAR Injections of N-iNSCs and Controls
Figure Area Comparison p Value
Figure 4
motor cortex
/ vehicle versus unaffected 0.0050
/ treated (PAR) versus unaffected 0.0099
/ treated (PAR) versus / vehicle 0.0307
striatum
/ vehicle versus unaffected 0.0120
/ treated (PAR) versus unaffected 0.0002
/ treated (PAR) versus / vehicle 0.0808
ventral forebrain
/ vehicle versus unaffected 0.0223
/ treated (PAR) versus unaffected 0.0006
/ treated (PAR) versus / vehicle 0.2432
Figure S2
motor cortex
/ vehicle versus unaffected 0.0014
/ treated (PAR) versus unaffected < 0.0001
/ treated (PAR) versus / vehicle 0.5702
striatum
/ vehicle versus unaffected 0.0023
/ treated (PAR) versus unaffected 0.0031
/ treated (PAR) versus / vehicle 0.0155
ventral forebrain
/ vehicle versus unaffected 0.0008
/ treated (PAR) versus unaffected 0.0445
/ treated (PAR) versus / vehicle 0.0095
Figure S3
motor cortex
/ vehicle versus unaffected 0.0551
/ treated (PAR) versus unaffected 0.0296
/ treated (PAR) versus / vehicle 0.5046
striatum
/ vehicle versus unaffected 0.0167
/ treated (PAR) versus unaffected 0.1658
/ treated (PAR) versus / vehicle 0.1800
ventral forebrain
/ vehicle versus unaffected 0.1444
/ treated (PAR) versus unaffected 0.7773
/ treated (PAR) versus / vehicle 0.2273
Definition of statistical significance: p < 0.05.
Molecular Therapy: Methods & Clinical Development10% of unaffected mice (Figure 5C). The lysosomal hexosaminidase
enzyme is upregulated as a result of lysosomal dysfunction.32,33 As ex-
pected, hexosaminidase was elevated in vehicle-injected Naglu/
mice compared with unaffected mice in all sections (Figure 5D).
Following engraftment in Naglu/ mice, a partial reduction of hex-
osaminidase was achieved in the pool of sections 1 and 2, with a sig-
nificant 1.2-fold reduction (p = 0.0127), in section 3, with a reduction
of 1.2-fold (p = 0.0166), and a 1.3-fold reduction in section 4
(p < 0.0001), but no difference was observed for sections 5 and 6,
which are farther away from the site of graft placement (Figure 5D).
To assess the effect of the N-iNCSs on MPS IIIB-associated
neuropathology, we carried out qualitative analysis of microglial
activation, astrocytosis, and lysosomal storage accumulation on
representative sections from rostral (at the level of the isocortex
and olfactory areas), middle (at the level where the fimbria of the
hippocampus appears), and caudal (at the level of the midbrain)120 Molecular Therapy: Methods & Clinical Development Vol. 10 Septepositions along the rostrocaudal axis of mice from each treatment
group (Figure 6). For each section, images were taken at high
magnification within three different regions. For the rostral section,
images were taken in the dorsal isocortex, the ventral isocortex, and
the olfactory area. For the middle section, images were taken in the
motor cortex, striatum, and ventral forebrain. In the caudal section,
the dorsal cortex, dorsal midbrain, and ventral midbrain were
imaged. In general, all neuropathological hallmarks (CD68, GFAP,
and Lamp 1) exhibited by Naglu/ mice were more pronounced
at 9 months of age compared with 2 months (Figures 6A–6C, low
magnification). However, CD68 (Figure 6A) and GFAP (Figure 6B)
immunoreactivity in intraparenchymally grafted Naglu/ mice
were markedly reduced at all three rostrocaudal levels examined
and were largely indistinguishable from the appearance of these
markers at the corresponding level of the brain in unaffected mice
(Figure 6). However, in the middle and caudal sections (farther
away from graft placement), some activated microglia and
astrocytes could still be detected in the grafted Naglu/ mice (Fig-
ures 6A and 6B, Middle and Caudal, box 1).
Lamp 1 immunoreactivity was markedly increased in untreated
9-month-old Naglu/mice compared with unaffected heterozygous
controls throughout all three levels along the rostrocaudal axis (Fig-
ure 6C). At 2 months of age, Lamp 1 staining in vehicle-injected
Naglu/ mice was at a relatively low level and highly variable, mak-
ing it difficult to see significant changes between vehicle-injected and
intraparenchymally grafted Naglu/ mice (Figure S3C, 1–3). How-
ever, 9 months post-transplantation there was a consistent and
more generalized decrease in Lamp 1 immunoreactivity in all three
rostrocaudal sections (Figure 6C). As seen for CD68 and GFAP, the
level of Lamp 1 immunoreactivity in the motor cortex and dorsal cor-
tex farther away from the graft placement in the middle and caudal
sections, respectively, remained similar to vehicle-treated Naglu/
mice (Figure 6C).
Taken together, these data provide evidence that graftedN-iNSCs can
persist for prolonged periods of time and not only still secrete signif-
icantly elevated levels of NAGLU enzyme but also have pronounced
effects on the neuropathology associated with MPS IIIB in mice.
DISCUSSION
MPS IIIB is caused by a deficiency in NAGLU activity, resulting in
accumulation of heparan sulfate glycosaminoglycan. Although the
exact mechanism of disease is unknown, this enzyme deficiency leads
to lysosomal pathology and a pronounced neuroimmune response.
Unlike recombinant NAGLU,20,21,32 we showed that NAGLU
produced by our N-iNSCs in vitro can be efficiently endocytosed by
deficient cells via M6PRs (Figure 2) and are capable of correcting
microglial activation, astrocytosis, and lysosomal storage accumula-
tion in vivo.
Two injection methods were used in the 2 months after grafting
experiments to determine the best route of delivery according
to the level of invasiveness and how much engraftment ismber 2018
Figure 5. NAGLU Corrected N-iNSCs Grafting and Characterization of Enzyme Activity at 9 Months
(A) Immunohistological staining of 40-mm representative sections for GFP, shown at low magnification, following PAR injection of N-iNSCs into Naglu/ mice. Post-
acquisition processing included adjustments to brightness and contrast and RGB curves using Adobe Photoshop CS6 to improve visibility and consistency in color tone.
Scale bar, 1 mm. (B) Schematic diagram depicting how the brains were divided. Brains were dissected sagittally along the midline first. One brain hemisphere was for
histology, and the other brain hemisphere was further sectioned into 2-mm-thick coronal slices in each animal. For NAGLU and hexosaminidase (HEX) activity assays, brain
sections 1 and 2 and 5 and 6 were pooled. The blue dots represent the approximate intraparenchymal injection sites. (C and D) Enzymatic activity of NAGLU (C) and HEX (D),
respectively, inNaglu/mice withN-iNSCs (/ treated) or saline (/ vehicle) compared with heterozygous control mice (unaffected). All bars showmean ± SD (n = 10–12
mice per group). Mean with SD. Two-tailed, unpaired parametric t tests were used between (/ treated) or saline (/ vehicle) groups.*p < 0.05, **p < 0.01, ****p < 0.0001.
www.moleculartherapy.orgachieved: injection into the ventricles (ICV) or directly into the stria-
tum (intraparenchymal). It has been shown previously that some
NSCs injected into the ventricles (ICV) are capable of widespread
engraftment and can differentiate into neurons or glia.16 In compar-
ison, the level of engraftment achieved 2 months after grafting using
ICV injection in our experiment was low (Figure 3). A greater level of
engraftment was achieved via the intraparenchymal route at this
time point, but the majority of these cells were detected within aMolecular Theconcentrated region of the ventral forebrain (Figure 3). Furthermore,
the degree of iNSC engraftment was inconsistent in this cohort of
mice. Not only was the level of engraftment variable, as assessed
by GFP immunostaining, but so was the level of NAGLU activity
produced by these grafts. Some animals possessed activity greater
than or equal to heterozygous controls, whereas others showed little
to no NAGLU activity. We speculate that the specific location of the
cells accounts for this variation.rapy: Methods & Clinical Development Vol. 10 September 2018 121
Figure 6. Correction of Neuropathology and Storage Accumulation in Naglu–/– Mice Treated with Neural Stem Cells Overexpressing NAGLU N-iNSCs at
9 Months
(A–C) Representative bright-field images of half-brain coronal sections from heterozygous control mice (unaffected) and mice injected with saline (/ vehicle) or N-iNSCs
(/ treated). Images were taken at three levels along the rostrocaudal axis (rostral, middle, and caudal) and immunohistochemically stained for CD68 (A), GFAP (B), and
Lamp 1 (C), respectively. Numbered boxes show images taken at higher magnification from three specific areas within each section (boxes 1–3, outlined at lower
magnification, top). The same three areas were analyzed for GFAP and Lamp 1. Post-acquisition processing was applied to all images and included adjustments to
brightness and contrast and RGB curves using Adobe Photoshop CS6 to improve visibility and consistency in color tone. Scale bars, 1 mm.
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www.moleculartherapy.orgThe level of engraftment and distribution of cells was different in our
long-term study than 2months after grafting, withmore cells detected
and a broader dispersion throughout the brain being achieved at
9 months. It seems likely that this discrepancy is due to a better initial
engraftment of N-iNSCs in the 9-month survival experiment. How-
ever, altered proliferation and or differentiation and spread of these
N-iNSCs cannot be excluded in a more diseased MPS IIIB brain,
and further experiments will be needed to distinguish between these
possibilities.
Based on the 9 months grafting experiments, our data show that the
ability of engrafted cells to correct pathology depends primarily on
the total level of engraftment rather than the precise distribution of
the cells because we observed almost complete correction in some re-
gions with low engraftment. Two months post-grafting, we docu-
mented the ability of iNSCs to correct nearby areas of pathology
and lysosomal storage accumulation when engraftment is localized.
Interestingly, as reported previously,34 neuroinflammation (micro-
glial activation and level of cytokines) is established even before
lysosomal storage accumulation reaches a significant level. Our data
suggest that the underlying disease mechanisms that lead to the neu-
roimmune response seen in MPS IIIB mice may not be a direct result
of storage accumulation and that overall neuropathology results from
a number of different events that converge at a particular pathological
endpoint. It is also plausible that a deficiency in NAGLU has other
consequences, aside from failing to simply break down heparan sul-
fate. In many neurodegenerative diseases, local activation of resident
microglia and astrocytes and infiltration of peripheral leucocytes as
part of a normally protective immune reaction can be toxic to neu-
rons.35,36 In other diseases, such as Cln3 disease, glia are themselves
affected by the disease and can harm neurons directly.37
Upregulation of GFAP and activation of astrocytes in the MPS IIIB
mouse brain has been widely reported.31,38 However, at 2 months,
in comparison with microglial activation, the ability of the engrafted
cells to temper astrocyte activation was less evident in the area where
they had immediately engrafted and even less so at a distance (Fig-
ure S2). This result could have several interpretations. For example,
it is possible that microglia require a lower threshold of NAGLU to
attenuate their activation or that microglia are more sensitive to
anti-inflammatory signals released by the injected NSCs. Although
we have not evaluated the anti-inflammatory properties of grafted
N-NSCs in this study, it has been reported that NSCs can exert this
function.39
As expected, our data showed that, at 9 months of age,Naglu/mice
display a more pronounced storage burden, microglial activation, and
astrocytosis than at a younger age. Transplanted cells were able to
provide at least 10% of heterozygote-level NAGLU activity
throughout the brain, consequently almost completely correcting
lysosomal storage accumulation and neuropathology. However,
even 21% of heterozygote-level NAGLU activity was not adequate
for complete dorsoventral correction of pathology, with the dorsal re-
gion of the cortex showing the least correction. This result could beMolecular Theexplained by the corpus callosum potentially acting as a physical bar-
rier for the diffusion of NAGLU enzyme to reach the cortex or the
considerable distance of the grafted cells from this cortical region.
However, in at least one animal, we did unexpectedly observe com-
plete correction of the olfactory bulb, which is farthest away from
the majority of engrafted cells. This suggests that the relationship be-
tween the level and sites of engraftment and the ability of N-iNSCs to
correct pathology is a complex one that is not fully understood.
Nevertheless, our data suggest that the relative amount and spread
of grafted cells, rather than their particular location, has the greatest
influence on disease-related pathology. Therefore, we speculate that
any strategy that promotes more widespread engraftment ofN-iNSCs
would improve their efficacy.
Our data provide evidence toward the potential of using NSCs over-
expressing NAGLU as a means to treat MPS IIIB. Indeed, NSC ther-
apies are in clinical trials to treat Parkinson’s disease, stroke, cancer,
amyotrophic lateral sclerosis (ALS), spinal cord injury, and Pelizaeus-
Merzbacher disease.40 Optimization of our injection procedure and
the properties of the NSC lines used to lead to greater engraftment
will be needed if this goal is to be realized.
MATERIALS AND METHODS
Lentivirus Production
The human NAGLU gene was engineered from a previously pub-
lished NAGLU-IGF220 sequence and further cloned into a lentiviral
backbone plasmid, pSAM-GFP (a gift from Dr. Michael Kyba,
University of Minnesota) at the XhoI and NotI sites. The resulting
expression vector was named pSAM-NAGLU-GFP. The lentiviral su-
pernatant was produced with 293T cells (American Type Culture
Collection, Manassas, Virginia) as described previously.41
Cellular Reprogramming
Naglu/ MEFs were transduced with the reprogramming factors
pMXs-OCT3/4, pMXs-SOX2, pMXs-KLF4, and pMXs-c-MYC
(Addgene, Cambridge, MA) as reported previously.18 MEFs were
cultured until individual iPSC colonies were formed. Colonies were
picked and grown individually on a feeder layer of MEFs treated
with mitomycin C (Roche, Indianapolis, IN) as described before.41
Characterization was performed using alkaline phosphatase staining
(Cell Biolabs, San Diego, CA) and immunofluorescence for the pres-
ence of Oct4 (see Immunocytochemistry).
Directed Differentiation of iPSCs to iNSCs
iPSCs were grown feeder-free at a density of 8.0  104 cells/well in
embryonic stem cell (ESC) medium (knockout DMEMwith 10% fetal
bovine serum [FBS] and 500 U/mL leukemia inhibitory factor; Milli-
pore, Burlington, MA). The next day, the medium was changed to
NSC medium (DMEM/F12 supplemented with B27 without vitamin
A and N2; Gibco, Carlsbad, CA) and grown for 12 days. On day 12,
NSC medium, 20 ng/mL of epidermal growth factor (EGF),
and 20 ng/mL basic fibroblast growth factor (bFGF) were added
(PeproTech, Rocky Hill, NJ). Cells were expanded in NSC medium +
EGF + bFGF as monolayers.19rapy: Methods & Clinical Development Vol. 10 September 2018 123
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Total RNA was extracted from iPSC clones with Trizol (Thermo
Fisher Scientific, Waltham, MA), and cDNA was generated using
1 mg DNase-treated RNA with oligo-dT primers and ThermoScript
reverse transcriptase (Thermo Fisher Scientific, Waltham, MA) ac-
cording to the manufacturer’s instructions. PCR reactions were run
in triplicate and quantified on a PikoReal real-time PCR system
(Thermo Fisher Scientific, Waltham, MA) using TaqMan real-time
PCR premixtures (Bioline, Taunton, MA) and the pre-made TaqMan
probes Nestin (Mm00450205_m1) and GAPDH (Mm99999915-g1)
(Applied Biosystems, Foster City, CA). Results were expressed as
gene expression level compared with GAPDH.
Enzyme Activity Assays
The catalytic activity of NAGLU was determined by hydrolysis of the
fluorogenic substrate 4-methylumbelliferyl-N-acetyl-a-glucosami-
nide (EMD Millipore, Burlington, MA) with a final concentration
of 0.1 mM substrate in the incubation mixture as described previ-
ously.20 The catalytic activity of b-hexosaminidase (combined A
and B isoforms) was determined by hydrolysis of 4-methylumbelli-
feryl-N-acetyl-b-glucosaminide (EMD Millipore, Burlington, MA)
using 1.25 mM substrate in the incubation mixture. A unit of activity
is defined as the release of 1 nmol of 4-methylumbelliferone (4MU)
per hour at 37C. Protein concentration was estimated by the Brad-
ford method, using BSA (Bio-Rad, Hercules, CA) as the standard.
Fluorescence was measured on a microplate reader (Spectramax
Paradigm, Molecular Devices, San Jose, CA) with lex 365 nm and
lem 445 nm. Intracellular NAGLU activity is presented as units per
milligram of protein, and secreted NAGLU is presented as units per
milliliter.
Endocytosis of Enzyme in Cell Culture
Naglu/ iNSCs were plated onto 12-well tissue culture plates at
1  105 cells per well and subsequently incubated with filtered
(0.45 mm) supernatants that were taken from T25 flasks containing
1  106 N-iNaglu/ NSCs. After 4 hr, the cells were washed and
lysed with mammalian protein extraction reagent (M-PER, Thermo
Fisher Scientific, Waltham, MA), and the lysates and filtered superna-
tant were assayed for enzyme activity as described above. Superna-
tants and cell lysates from Naglu/ iNSCs served as negative
controls, and supernatants and cell lysates from WT iPSCs served
as positive controls.
LysoTracker Staining
LysoTracker (Thermo Fisher Scientific, Waltham, MA) staining was
performed following the manufacturer’s procedure. Briefly, cells
were stained with 150 nM LysoTracker in relevant culture medium
for 1 hr at 37C and 5% CO2. Following incubation, cells were washed
twice with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and
1.76 mM KH2PO4 [pH 7.4]) and analyzed by FACS.
Immunocytochemistry
Cells were plated on glass coverslips and grown in appropriate media.
Cells were fixed with 4% paraformaldehyde. Primary antibodies used124 Molecular Therapy: Methods & Clinical Development Vol. 10 Septewere monoclonal mouse anti-Olig2 (Thermo Fisher Scientific, Wal-
tham, MA; catalog no. MA5-15810), monoclonal mouse anti-Nestin
(Invitrogen Carlsbad, CA; catalog no. 14584380), polyclonal rabbit
anti-MAP2 (Thermo Fisher Scientific, Waltham, MA; catalog no.
PA5-17646), polyclonal rabbit anti-GFAP (Agilent Technologies,
Santa Clara, CA; catalog no. Z0334), and mouse anti-Tuj1 (The
Developmental Studies Hybridoma Bank [DSHB], Iowa City, IA; cat-
alog no. 6g7) (all 1:400). The following secondary antibodies were
selected according to the primary antibody used: goat anti-mouse
Alexa 488, catalog no. A10640 (Olig2); goat anti-mouse Alexa 555,
catalog no. A21424 (Nestin); goat anti-rabbit Alexa 4888, catalog
no. A11008 (MAP2); goat anti-rabbit Alexa 555, catalog no.
A21428 (GFAP); and goat anti-mouse Alexa 555, catalog no.
A21424 (Tuj-1) (all from Molecular Probes, Eugene, OR; 1:1,000
dilution).
Experimental Animals
Animal experiments were approved by the Institutional Animal Care
and Use Committee at the Los Angeles Biomedical Research Institute
at Harbor-UCLA Medical Center, which is accredited by the Associ-
ation for Assessment and Accreditation of Laboratory Animal Care
(AAALAC). The Naglu/ knockout mouse was a gift from Dr. Neu-
feld from the University of California, Los Angeles (UCLA) and was
back-bred onto C57BL6/J.42 Genotyping was performed with the
following primers: NAG50, 50-TGGACCTGTTTGCTGAAAGC-30;
NAG30, 50-CAGGCCATCAAATCTGGTAC-30; Neo50, 50-TGGGAT
CGGCCATTGAACAA-30; and Neo30, 50-CCTTGAGCCTGGCGA
ACAGT-30. Naglu+/ females were crossed with Naglu/ males to
obtain homozygous affected mice and heterozygous controls. Exper-
iments were performed on age-matched mice (usually littermates) of
either gender.
Injection of NSCs
2.5  105 NAGLU-overexpressing NSCs (N-iNSC) in 3 ml of PBS or
PBS alone were injected bilaterally on post-natal day 0 (P0) or P1
neonates of Naglu/ mice under cryo-anesthesia by Hamilton
syringe with 32G needles. The injection site for ICV injection was
about 2.5 mm between the bregma and the eyes and 2 mm away later-
ally from the sagittal suture and 2.5-mm depth. For intraparenchymal
injection, it was about 3.0 mm between the bregma and the eyes and
4.0 mm away laterally from the sagittal suture and 3.0 mm depth.
Percoll Gradient Centrifugation
To isolate lysosomes, a Percoll gradient was constructed as follows:
one part 10 PBS was added to nine parts Percoll (Sigma-Aldrich,
St. Louis, MO) to make a stock isotonic solution. Then the stock
isotonic Percoll was diluted to a 30% concentration in PBS, and
Hibernate A (GIBCO, Carlsbad, CA) was placed above the 30% Per-
coll layer.
Brains were digested using a 1:1 mixture of Accutase (STEMCELL
Technologies, Vancouver, Canada) and trypsin (GIBCO, Carlsbad,
CA) for 1 hr at 37C. Mechanical dissociation was achieved using
18G needles followed by 25G needles for 10 repetitions each. Brainmber 2018
www.moleculartherapy.orghomogenates were added to the Percoll gradient and centrifuged at
1,200 g for 45 min. Debris in the top layer was aspirated, the Percoll
gradient was diluted in PBS, and samples were centrifuged at 3, 000 g.
Cells were then processed for FACS or lysed for enzymatic assays.
Tissue Harvesting, Processing, and Histological Staining
After 2 and 9 months post-transplantation, brains were dissected
sagittally along the midline, and left hemispheres were post-fixed
overnight at 4C in 4% paraformaldehyde (PFA) before cryoprotec-
tion at 4C in a solution of 30% sucrose in Tris-buffered saline. The
right brain hemispheres were further sectioned into 2 mm-thick cor-
onal slices using an adult mouse brain slicer matrix (Zivic Instru-
ments, Pittsburgh, PA) and rapidly frozen and stored at 80C until
performing NAGLU and b-hexosaminidase activity assays. 40-mm
frozen coronal sections were cut through the rostrocaudal extent of
the cortical mantle (Microm HM 430 freezing microtome, Thermo
Fisher Scientific, Waltham, MA). Sections were collected in a cryo-
protectant solution (tris-buffered saline [TBS]/30% ethylene glycol/
15% sucrose/0.05% sodium azide) and stored at 4C before histolog-
ical processing.43–45
Immunohistochemistry for Assessing Stem Cell Engraftment,
Glial Markers, and Storage Accumulation
To examine the level of stem cell engraftment, the extent of glial
activation and storage material accumulation, adjacent one-in-six
series of free-floating frozen sections were immunohistochemically
stained using the following standard immunoperoxidase protocol,
as described previously.43–45 Anti-GFP (1:10,000 dilution, Invitro-
gen, catalog no. A10259), polyclonal rabbit anti-GFAP (1:8,000 dilu-
tion, Agilent Technologies, Santa Clara, CA; catalog no. Z0334), rat
anti-CD68 (1:2,000, Bio-Rad, Hercules, CA; catalog no. MCA1957),
and rat anti-Lamp 1 (1:4,000, DSHB, Iowa City, IA; catalog no.
1D4B), and rabbit immunoglobulin G (IgG) fraction were used, fol-
lowed by the appropriate secondary antiserum: biotinylated goat
anti-rabbit IgG (1:1,000, Vector Laboratories, Burlingame, CA; cat-
alog no. BA-1000), biotinylated swine anti-rabbit IgG (GFAP, Agi-
lent Technologies, Santa Clara, CA; catalog no. E0353), biotinylated
rabbit anti-rat IgG (CD68, Vector Laboratories, Burlingame, CA;
catalog no. BA-4001), and biotinylated goat anti-rat IgG (Lamp 1,
Vector Laboratories, Burlingame, CA; catalog no. BA-9400), all
1:1,000 dilution. Sections were incubated in an avidin-biotin-perox-
idase complex kit (Vectastain Elite ABC Kit, Vector Laboratories,
Burlingame, CA). Immunoreactivity was visualized by incubation
in 0.05% 3’, 3’-diaminobenzidine (DAB; Sigma-Aldrich, St. Louis,
MO) and 0.001% H2O2 in TBS for 10 min, a time that represents
saturation for this reaction.
Quantitative Analysis of Glial Phenotype and Storage
Accumulation
To analyze the degree of glial activation and storage material accumu-
lation in the motor cortex, striatum, and ventral forebrain of sections
stained for GFAP, CD68, and Lamp 1, an adapted semi-automated
thresholding image analysis method43,46 was used with Image-Pro
Premier software (Media Cybernetics, Rockville, MD). Each regionMolecular Theof interest was defined according to neuroanatomical landmarks
described by Paxinos and Franklin47 across three sections. The sec-
tions selected included the section corresponding to the greatest level
of engraftment and the sections immediately before and after.
Statistical Analysis
All statistical analyses were performed using Prism software
(GraphPad, La Jolla, CA). A two-tailed, unpaired, parametric t test
was used when two groups were compared. Results were considered
statistically significant when p < 0.05. Unless otherwise stated, statis-
tical comparisons are between untreated MPS IIIB mice and unaf-
fected heterozygous controls and the treatment groups and untreated
MPS IIIB mice. One-way ANOVA was used to compare groups
greater than two.
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